Trial Profile
A phase I/II multicentric study to determine the safety and efficacy of a combination of Anti-CD3 & Anti-CD7 ricin A immunotoxins for the treatment of steroid-resistant acute graft-versus-host disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 06 May 2009
Price :
$35
*
At a glance
- Drugs Anti-CD3-ricin chain A conjugate/anti-CD7-ricin chain A conjugate (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 01 May 2009 Planned initiation date changed from 1 Nov 2008 to 1 Jan 2010 as reported by ClinicalTrials.gov.
- 01 May 2009 Planned end date changed from 1 Nov 2010 to 1 Jan 2012 as reported by ClinicalTrials.gov.
- 27 Oct 2008 Planned initiation date changed from 1 Sep 2008 to 1 Nov 2008 as reported by ClinicalTrials.gov.